The $3.4 Billion Lesson Pharma Faces in Shelved Drugs
Thousands of shelved drug candidates could unlock therapies for rare diseases, but funding and partnerships lag. The ...
Identify the Dividend Aristocrats ETF with the lowest fees and understand how fee selection affects long-term performance.
27,609 articlesThousands of shelved drug candidates could unlock therapies for rare diseases, but funding and partnerships lag. The ...
Epic Fury is spreading beyond energy prices, hitting travel, remittances, and food imports in Asia. The resulting pol...
The U.S. is expanding its military footprint in the Middle East, adding three amphibious ships and 2,500 Marines. Mar...
Two Kalshi veterans are raising up to $35 million for a new prediction-market VC fund called 5c(c) Capital, backed by...
When a chief operating officer sells shares, investors often wonder what it really means. This guide explains how to ...
Asia is turning to U.S. LNG suppliers as disruptions in the Middle East squeeze global gas flows. The response is swi...
LayerZero's cross-chain protocol is now active on the Canton Crypto Network, linking a Goldman Sachs-backed instituti...
Silicon valley's tech right is steering AI and crypto bets toward policy-friendly outcomes. Critics warn the approach...
Apple reports strong Q2 2026 results, led by iPhone demand and Services, while signaling a shift toward ambient AI th...
Stocks rise on May 7, 2026 as AI-driven demand powers gains in the S&P 500 and SPY. Traders weigh earnings catalysts ...
Match Group revived a shuttered internship, drawing tens of thousands of applicants for a handful of slots, underscor...
As markets swing in 2026, investors revisit Ted Turner's risk-taking era, drawing lessons on diversification, leverag...